KR20190032436A - 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 - Google Patents

폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 Download PDF

Info

Publication number
KR20190032436A
KR20190032436A KR1020197004681A KR20197004681A KR20190032436A KR 20190032436 A KR20190032436 A KR 20190032436A KR 1020197004681 A KR1020197004681 A KR 1020197004681A KR 20197004681 A KR20197004681 A KR 20197004681A KR 20190032436 A KR20190032436 A KR 20190032436A
Authority
KR
South Korea
Prior art keywords
weeks
subject
treatment
months
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197004681A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 올리버
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20190032436A publication Critical patent/KR20190032436A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020197004681A 2016-07-21 2017-07-19 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 Ceased KR20190032436A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365017P 2016-07-21 2016-07-21
US62/365,017 2016-07-21
PCT/IB2017/054360 WO2018015897A1 (en) 2016-07-21 2017-07-19 Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis

Publications (1)

Publication Number Publication Date
KR20190032436A true KR20190032436A (ko) 2019-03-27

Family

ID=59683618

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004681A Ceased KR20190032436A (ko) 2016-07-21 2017-07-19 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도

Country Status (7)

Country Link
US (2) US20210292404A1 (cg-RX-API-DMAC7.html)
EP (1) EP3487584A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019521161A (cg-RX-API-DMAC7.html)
KR (1) KR20190032436A (cg-RX-API-DMAC7.html)
AU (2) AU2017298656A1 (cg-RX-API-DMAC7.html)
CA (1) CA3031346A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018015897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease

Also Published As

Publication number Publication date
AU2017298656A1 (en) 2019-02-07
US20220177570A1 (en) 2022-06-09
EP3487584A1 (en) 2019-05-29
WO2018015897A1 (en) 2018-01-25
AU2017298656A2 (en) 2019-03-28
US20210292404A1 (en) 2021-09-23
CA3031346A1 (en) 2018-01-25
AU2020207771A1 (en) 2020-08-06
JP2019521161A (ja) 2019-07-25

Similar Documents

Publication Publication Date Title
Lukey et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Kim et al. Quality matters as much as quantity of skeletal muscle: clinical implications of myosteatosis in cardiometabolic health
Burgel The role of small airways in obstructive airway diseases
Lim et al. Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole
Chen et al. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography
Casu et al. Can changes in renal function predict variations in β-lactam concentrations in septic patients?
Dayton et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies
Farahi et al. In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients
Santer et al. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial
EP2844291B1 (en) Methods for treating idiopathic pulmonary fibrosis
Ohar et al. Diffusing capacity decreases after heart transplantation
Chen et al. [18F] fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation
Washko et al. Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE
Camilo et al. Pulmonary function testing and chest tomography in patients with acromegaly
Gibson et al. Ventilation heterogeneity is a treatable trait in severe asthma
US20220177570A1 (en) Use of the il-1beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis
von Haehling et al. Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial
Ward et al. Interstitial lung disease: An approach to diagnosis and management
Keppler-Noreuil et al. Phenotypic features of cystic lung disease in proteus syndrome: a clinical trial
Villalobos et al. Exploring the efficacy of benralizumab in chronic eosinophilic pneumonia following corticosteroid therapeutic failure: a case report
WO2022061812A1 (zh) 醋酸格拉替雷在制备Aβ42毒性抑制剂和清除剂中的应用
Fragni Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model
Kerget et al. Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism.
RU2386397C1 (ru) Способ диагностики функциональных изменений у больных с цервикальной дистонией
Okudan et al. Detection of alveolar epithelial injury by Tc-99m DTPA radioaerosol inhalation lung scan in rheumatoid arthritis patients

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220511

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I